Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 7
The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL
An analysis of key updates on CAR T-cell therapy in DLBCL from ZUMA-7 and TRANSFORM trials, exploring its potential as a primary second-line option, along with insights into efficacy and safety data for transplant-ineligible patients from ALYCANTE and PILOT studies
Video content above is prompted by the following:
What are the key takeaways from the most recent update of Axi-Cel in DLBCL (ZUMA-7: Westin et al. NEJM 2023) and Liso-Cel in DLBCL (TRANSFORM: Abramson et al. Blood 2023)?
- Do you think these studies support CAR T-cell therapy as the primary option for 2L treatment?
- Do you foresee CAR T-cell therapy becoming the primary 2L treatment option? If so, when do you see this occurring?
For transplant ineligible patients, what does efficacy and safety data for CAR T-cell therapy look like? Please briefly review and discuss key takeaways from ALYCANTE (Houot et al. Nature 2023) and PILOT (Sehgal et al. JCO 2022).